RHRoderick Eliot Hubbard

Roderick Eliot Hubbard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roderick Eliot Hubbard has a total of 269 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding

    by Matyas Pal Timari, Attila Paczal, Andras Herner, Mark Molnar, Zoltan Madarasz, Miklos Nyerges, Simon T. Bedford, Teresa Brooks, James Davidson, Zoe Daniels, et al.

    Evasion of apoptosis is a hallmark of cancer. Deregulation of BCL-XL, a member of the BCL-2 family of proteins, has been linked to the development of various tumor types. This study presents the design and synthesis of BCL-XL inhibitors with novel mono- and bicyclic cores. The new structural features were optimized to combine high binding efficiency with the opening of diverse novel vectors for additional modifications. The lead compounds exhibited picomolar affinities and significant cellular potency in the BCL-XL-dependent MOLT-4 cell line, which also translated into marked tumor growth inhibition in a xenograft study. These findings highlight the potential of BCL-XL inhibitors as therapeutic agents in cancer treatment by targeting the apoptotic intrinsic pathway.


  • Open Access

    Targeting PTPN22 at Nonorthosteric Binding Sites─A Fragment Approach

    by Paola Di Lello, Marta M. Wells, Ben Davis, Zoe Daniels, Thomas P. Garner, Lewis Gazzard, Richard Harris, Roderick E. Hubbard, Matthew L. Landry, Bryan Martin, et al.

    Nonreceptor protein tyrosine phosphatase 22 (PTPN22) is a known negative regulator of T cell receptor signaling. PTPN22’s pro-autoimmune variant (C1858T) was found to have a risk preventive association with multiple types of cancer, to contribute to improved overall survival in patients treated with the anti-PD-L1 atezolizumab, and to enhance tumor immunity in mice. Modulating the activity of phosphatases has been historically challenging due to the polar and conserved nature of the orthosteric sites across the protein family. In this work, we outline a strategy for discovering and characterizing nonorthosteric ligands of the PTPN22 phosphatase domain. We opted for a fragment screen to identify ligands of PTPN22 and utilized a multidisciplinary approach to characterize them. This included the integration of experimental data-driven molecular dynamics when cocrystallization of fragments with PTPN22 was unsuccessful. With this approach, we identified and advanced fragments that bind PTPN22 at two novel nonorthosteric sites. Due to the shared tertiary structure of the phosphatase domain, we believe this hit finding effort, combined with knowledge about the allosteric circuitry of phosphatases, can provide synergistic value.


  • Open Access

    Design, Modular Synthesis and Screening of 58 Shape-Diverse 3-D Fragments

    by Peter O'BRien, Thomas D. Downes, S. Paul Jones, James D. Firth, John F. Darby, Amelia K. Gilio, Hanna F. Klein, Xinyu Wang, David C. Blakemore, Claudia De Fusco, et al.

    Fragment-based drug discovery is widely used in both academia and industry during the early stages of drug discovery. There is a growing interest in the design of 3-D fragments for inclusion in fragment libraries in order to increase chemical space coverage. We present herein the design and synthesis of 58 shape-diverse 3-D fragments that are prepared using just three modular synthetic methodologies. The 3-D fragments comprise a cyclic scaffold (cyclopentane, pyrrolidine, piperidine, tetrahydrofuran or tetrahydropyran) with one aromatic or heteroaromatic ring and possess properties within ‘rule-of-three’ fragment space. 3-D shape is assessed using principal moments of inertia analysis and conformational diversity is achieved by considering all conformations up to 1.5 kcal mol-1 above the energy of the global minimum energy conformer. Due to the modular nature of the fragment syntheses, these 3-D fragments are synthetically-enabled for fragment elaboration follow-on work, a key design feature. This modular, shape-diverse 3-D fragment collection has delivered privileged starting points across a spectrum of targets. Fragments from the set have been crystallographically validated in the SARS-CoV-2 main protease (Mpro) and the nonstructural protein 3 (Nsp3) (Mac1) as well as human glycosyltransferase MGATV, a major enzyme in the mammalian N-glycosylation pathway and a promoter of aggressive metastatic cancers, underscoring the breadth of biological space that can be explored.

  • Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity

    by Attila Vasas, Lisa Ivanschitz, Balázs Molnár, Árpád Kiss, Lisa Baker, Andrea Fiumana, Alba Macias, James B. Murray, Emma Sanders, Neil Whitehead, et al.

    Inhibition of ubiquitin-specific protease 7, USP7, has been proposed as a mechanism to affect many disease processes, primarily those implicated in oncology. The bound crystal structure of a published high-throughput screening hit with low-micromolar affinity for USP7 identified three regions of the compound for structure-guided optimization. Replacing one side of the compound with different aromatic moieties gave little improvement in affinity, and the central piperidine could not be improved. However, the binding site for the other side of the compound was poorly defined in the crystal structure, which suggested a wide variety of synthetically accessible options for optimization. These were assessed by screening reaction mixtures that introduced different substituents to this other side. Subsequent optimization led to a compound with low-nanomolar affinity for USP7, which showed target engagement in tumors, was tolerated in mice, and showed efficacy in xenograft models.


  • Open Access

    Expanding the scope of a catalogue search to bioisosteric fragment merges using a graph database approach

    by Stephanie Wills, Ruben Sanchez-Garcia, Stephen D. Roughley, Andy Merritt, Roderick E. Hubbard, Frank von Delft, Charlotte M. Deane

    The efficiency of fragment-to-lead optimization could be improved by automated workflows for the design of follow-up compounds. Pipelines that are able to fully exploit the interaction opportunities identified from the crystal structures of bound fragments would greatly aid this goal. To do so, these pipelines need to require minimal intervention from the user and be computationally efficient. In this work, we describe an updated version of our fragment merging methodology, which provides several feature enhancements, primarily by expanding the chemical space searched, allowing the identification of more diverse follow-up compounds, thus maximizing the chances of finding successful hits. While the original method focused on finding ‘perfect merges’, meaning compounds that directly incorporate substructures from the original fragments, here we expand the search to what we term ‘bioisosteric merges’, involving the incorporation of substructures that replicate the pharmacophoric features of the original fragments but may not be exactly identical. Unlike existing pharmacophore and shape-based descriptors used for virtual screening, this approach combines the search for these properties with the incorporation of novelty, which is necessary when searching for ways to link together distinct substructures. Compared with ‘perfect merging’, our new approach is able to find compounds that are directly informed by structures within the original fragments but are more chemically diverse. We contrast our approach with the use of a pharmacophore-constrained docking pipeline, run in parallel for select fragment pairs, and show that our method requires between 1.1-45.9-fold less computational time for conformer generation per merging ‘hit’ identified, referring to compounds that show a favourable degree of shape and colour overlap and recapitulation of original fragment interactions. Overall, our results show that our method has potential to be used to generate designs inspired by all fragments within a given pocket.


  • A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase

    by Naoki Kuki, David L. Walmsley, Kazuo Kanai, Sho Takechi, Masao Yoshida, Ryo Murakami, Kohei Takano, Yuichi Tominaga, Mizuki Takahashi, Shuichiro Ito, et al.

    Several generations of ATP-competitive anti-cancer drugs that inhibit the activity of the intracellular kinase domain of the epidermal growth factor receptor (EGFR) have been developed over the past twenty years. The first-generation of drugs such as gefitinib bind reversibly and were followed by a second-generation such as dacomitinib that harbor an acrylamide moiety that forms a covalent bond with C797 in the ATP binding pocket. Resistance emerges through mutation of the T790 gatekeeper residue to methionine, which introduces steric hindrance to drug binding and increases the Km for ATP. A third generation of drugs, such as osimertinib were developed which were effective against T790M EGFR in which an acrylamide moiety forms a covalent bond with C797, although resistance has emerged by mutation to S797. A fragment-based screen to identify new starting points for an EGFR inhibitor serendipitously identified a fragment that reacted with C775, a previously unexploited residue in the ATP binding pocket for a covalent inhibitor to target. A number of acrylamide containing fragments were identified that selectively reacted with C775. One of these acrylamides was optimized to a highly selective inhibitor with sub-1 μM activity, that is active against T790M, C797S mutant EGFR independent of ATP concentration, providing a potential new strategy for pan-EGFR mutant inhibition.


  • Open Access

    Fragment Merging Using a Graph Database Samples Different Catalogue Space than Similarity Search

    by Stephanie Wills, Ruben Sanchez-Garcia, Tim Dudgeon, Stephen D. Roughley, Andy Merritt, Roderick E. Hubbard, James Davidson, Frank von Delft, Charlotte M. Deane

    Fragment merging is a promising approach to progressing fragments directly to on-scale potency: each designed compound incorporates the structural motifs of overlapping fragments in a way that ensures compounds recapitulate multiple high-quality interactions. Searching commercial catalogues provides one useful way to quickly and cheaply identify such merges and circumvents the challenge of synthetic accessibility, provided they can be readily identified. Here, we demonstrate that the Fragment Network, a graph database that provides a novel way to explore the chemical space surrounding fragment hits, is well-suited to this challenge. We use an iteration of the database containing >120 million catalogue compounds to find fragment merges for four crystallographic screening campaigns and contrast the results with a traditional fingerprint-based similarity search. The two approaches identify complementary sets of merges that recapitulate the observed fragment-protein interactions but lie in different regions of chemical space. We further show our methodology is an effective route to achieving on-scale potency by retrospective analyses for two different targets; in analyses of public COVID Moonshot and Mycobacterium tuberculosis EthR inhibitors, potential inhibitors with micromolar IC50 values were identified. This work demonstrates the use of the Fragment Network to increase the yield of fragment merges beyond that of a classical catalogue search.


  • Open Access

    Data from Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

    by Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, et al.

  • Open Access

    Adobe PDF - MCT-07-0149--Suppl_Data.pdf from Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

    by Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, et al.

  • Open Access

    Data from Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

    by Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, et al.